Isomorphic Labs, a spinoff from Google, raised $600 million to improve AI-driven drug development. Thrive Capital led this funding round with support from Google Ventures and additional investments from Alphabet. Founded in 2021, Isomorphic Labs originated from Google DeepMind. CEO Sir Demis Hassabis stated that the investment will expedite the development of their AI drug design engine and enhance clinical programs to target diseases. This achievement reflects a growing trend of startups using AI in drug development, as evidenced by Xaira Therapeutics raising $1 billion and Formation Bio securing $372 million. Thrive Capital, co-founded by Joshua Kushner, has a history of significant investments, including a $10 billion round for Databricks and participation in a funding round for OpenAI.

Learn more on this news visit us at:

https://theweb3.news/news-bites/is-isomorphic-labs-about-to-revolutionize-drug-development-with-ai/

Hosted on Acast. See acast.com/privacy for more information.